Liquidia (LQDA) Liabilities and Shareholders Equity (2019 - 2026)

Liquidia's (LQDA) quarterly Liabilities and Shareholders Equity came in at $401.5 million in Q1 2026, up 76.55% year-on-year from $227.4 million in Q1 2025, and up 22.44% quarter-over-quarter from $327.9 million in Q4 2025.

Liquidia (LQDA) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends

Liquidia's Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $401.5 million for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 76.55% year-over-year to $401.5 million in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 42.22% increase from a year earlier, with the FY2025 full-year figure at $327.9 million, up 42.39% from the prior year.
  • Liabilities and Shareholders Equity climbed to $401.5 million in Q1 2026 per LQDA's latest filing, from $327.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $401.5 million in Q1 2026 and bottomed at $93.5 million in Q1 2022.
  • The 5-year median for Liabilities and Shareholders Equity is $177.4 million (2024), against an average of $195.5 million.
  • Across the five-year window, Liabilities and Shareholders Equity retreated 15.79% in 2023 and surged 126.52% in 2024, its largest moves.
  • Year by year, Liabilities and Shareholders Equity stood at $129.2 million in 2022, then declined by 8.41% to $118.3 million in 2023, then surged by 94.63% to $230.3 million in 2024, then soared by 42.39% to $327.9 million in 2025, then increased by 22.44% to $401.5 million in 2026.
  • Per Business Quant, the three latest LQDA Liabilities and Shareholders Equity figures stand at $401.5 million (Q1 2026), $327.9 million (Q4 2025), and $276.0 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 43.40 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 40.04 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 15.15 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 98.91 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 6.71 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - 69.30 Bn
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 36.83 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 4.91 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 13.22 Bn
10 Liquidia 7.84 Bn 7.61 Bn 121.79 Mn 401.53 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 401.53 Mn
Dec 31, 2025 327.93 Mn
Sep 30, 2025 275.98 Mn
Jun 30, 2025 257.41 Mn
Mar 31, 2025 227.43 Mn
Dec 31, 2024 230.31 Mn
Sep 30, 2024 252.89 Mn
Jun 30, 2024 177.36 Mn
Mar 31, 2024 197.12 Mn
Dec 31, 2023 118.33 Mn
Sep 30, 2023 111.64 Mn
Jun 30, 2023 121.60 Mn
Mar 31, 2023 128.92 Mn
Dec 31, 2022 129.20 Mn
Sep 30, 2022 132.57 Mn
Jun 30, 2022 139.08 Mn
Mar 31, 2022 93.53 Mn
Dec 31, 2021 93.73 Mn
Sep 30, 2021 100.30 Mn
Jun 30, 2021 104.38 Mn